作者
Eric Boersma, Robert A Harrington, David J Moliterno, Harvey White, Pierre Théroux, Frans Van de Werf, Anneke de Torbal, Paul W Armstrong, Lars C Wallentin, Robert G Wilcox, John Simes, Robert M Califf, Eric J Topol, Maarten L Simoons
发表日期
2002/1/19
期刊
The Lancet
卷号
359
期号
9302
页码范围
189-198
出版商
Elsevier
简介
Background
Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce cardiac complications in patients undergoing percutaneous coronary intervention. The clinical efficacy of these drugs in acute coronary syndromes, however, is still unclear. We did a meta-analysis of all large randomised trials designed to study the clinical efficacy and safety of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes who were not routinely scheduled to undergo early coronary revascularisation.
Methods
Inclusion criteria were: randomisation of patients with acute coronary syndromes but without persistent ST elevation; comparison of a glycoprotein IIb/IIIa inhibitor with placebo or control therapy; non-recommendation of early coronary revascularisation during study-drug infusion; and enrolment of at least 1000 patients. Data on individual patients were obtained from all participants in these trials.
Findings
Six …
引用总数
学术搜索中的文章
E Boersma, RA Harrington, DJ Moliterno, H White… - The Lancet, 2002